Sep 15, 2021 / 07:45PM GMT
Catherine Walden Ramsey Schulte - Robert W. Baird & Co. Incorporated, Research Division - Senior Research Analyst
All right. Hi, everyone. Thanks for joining us today. I'm Catherine Schulte. I cover life sciences and diagnostics here at Baird. We're very excited to have Natera here with us today. And representing the company, we have Steve Chapman, CEO; and Mike Brophy, CFO. Just before we begin, a reminder to view the Baird's website and our published research for important disclosures about what we'll be discussing today. We're just going to jump right into Q&A. So if anyone in the audience has any questions, please submit them via the portal, and we will try to work them in.
So with that, Steve, Mike, thanks so much for joining us.
Steve Leonard Chapman - Natera, Inc. - CEO, President & Director
Thanks for having us.
Michael Brophy - Natera, Inc. - CFO
Thanks for having us.
Natera Inc at Robert W Baird Global Healthcare Conference (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
